Overexpression of Ubiquilin4 is associated with poor prognosis in patients with cervical cancer

Table 1 Relationship between Ubiquilin4 protein expression and clinicopathological features in 117 cases of cervical cancer

Variables		UBQLN4 expression		Total	Χ2	P value
		Low	High
Age (yr)					0.713	0.398
	≤ 45	34	24 (41.4%)	58
	> 45	30	29 (49.2%)	59
	Null
Pathologic type					0.244	0.885
	AD	2	1 (33.3%)	3
	ASC	3	2 (40.0%)	5
	SCC	59	50 (45.9%)	109
Lymph node metastasis					0.242	0.623
	No	53	42 (44.2%)	95
	Yes	11	11 (50.0%)	22
Histological grade					1.518	0.279
	I/II	16	12 (42.9%)	28
	III	39	50 (56.2%)	89
FIGO stage (2018)					0.242	0.623
	I/II	53	42 (44.2%)	95
	III	11	11 (50.0%)	22

AD: Adenocarcinoma; ASC: Adenosquamous carcinoma; SCC: Squamous cell carcinoma.

Table 2 Univariate and multivariate analyses of the factors correlated with overall survival and disease-free survival

Clinical variables	Univariate analysis (PFS)			Multivariate analysis (PFS)			Univariate analysis (OS)			Multivariate analysis (OS)
	HR	95%CI	P value1	HR	95%CI	P value1	HR	95%CI	P value	HR	95%CI	P value1
UBQLN4 (low vs high)	3.026	1.524-6.006	0.002	2.261	1.115-4.583	0.024	4.357	1.962-9.679	0	2.93	1.284-6.683	0.011
Age (≤ 45 vs > 45)	4.944	2.261-10.809	0	4.331	1.953-9.605	0	7.171	2.763-18.611	0	5.927	2.241-15.678	0
Grade (I/II vs III)	1.819	0.805-4.108	0.15				2.444	0.913-6.542	0.075
FIGO stage (I/II vs III)	2.869	1.983-4.151	0	2.659	1.807-3.911	0	3.372	2.234-5.089	0	3.048	1.968-4.72	0

¹Statistically significant (P < 0.05).

UBQLN4: Ubiquilin4; OS: Overall survival; PFS: Progression-free survival.